India Health Minister Backs Ranbaxy In Blaming U.S. Lobbyists
This article was originally published in PharmAsia News
India's health ministry sides with Ranbaxy International and its contention lobbyists for U.S. drug makers were responsible for the U.S. FDA's ban on 30 of the company's drugs. Health Secretary Naresh Dayal said the FDA already had approved the drugs and had never expressed problems with them before it started its investigation in February, 2006. He suggested the lobbyists persuaded a congressional committee to raise the issue, to which the FDA would have to respond. "All these are non-tariff barriers" raised because the United States is a growing market for Indian generics, he said. (Click here for more
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.